Evidence map›Paper›PMID 34165077›Full record

ArticleeLife2021

Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries.

Katy Am Gaythorpe, Kaja Abbas, John Huber, Andromachi Karachaliou, Niket Thakkar, Kim Woodruff, Xiang Li, Susy Echeverria-Londono, VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease, Matthew Ferrari and 5 more

Abstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Katy Am Gaythorpe *MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-3734-9081
Kaja Abbas *Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
John Huber *Department of Biological Sciences, University of Notre Dame, South Bend, United States.ORCID http://orcid.org/0000-0001-5245-5187
Andromachi Karachaliou *Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.
Niket Thakkar *Institute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, United States.
Kim WoodruffMRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-4618-8267
Xiang LiMRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
Susy Echeverria-LondonoMRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, United Kingdom.
VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease
Matthew Ferrari *Pennsylvania State University, University Park, United States.
Michael L Jackson *Kaiser Permanante Washington, Seattle, United States.
Kevin McCarthy *Institute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, United States.
T Alex Perkins *Department of Biological Sciences, University of Notre Dame, South Bend, United States.ORCID https://orcid.org/0000-0002-7518-4014
Caroline Trotter *Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.
Mark Jit *Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0001-6658-8255

Funding

Medical Research Council MC_PC_19012Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

Background: Childhood immunisation services have been disrupted by the COVID-19 pandemic. WHO recommends considering outbreak risk using epidemiological criteria when deciding whether to conduct preventive vaccination campaigns during the pandemic. Methods: We used two to three models per infection to estimate the health impact of 50% reduced routine vaccination coverage in 2020 and delay of campaign vaccination from 2020 to 2021 for measles vaccination in Bangladesh, Chad, Ethiopia, Kenya, Nigeria, and South Sudan, for meningococcal A vaccination in Burkina Faso, Chad, Niger, and Nigeria, and for yellow fever vaccination in the Democratic Republic of Congo, Ghana, and Nigeria. Our counterfactual comparative scenario was sustaining immunisation services at coverage projections made prior to COVID-19 (i.e. without any disruption). Results: Reduced routine vaccination coverage in 2020 without catch-up vaccination may lead to an increase in measles and yellow fever disease burden in the modelled countries. Delaying planned campaigns in Ethiopia and Nigeria by a year may significantly increase the risk of measles outbreaks (both countries did complete their supplementary immunisation activities (SIAs) planned for 2020). For yellow fever vaccination, delay in campaigns leads to a potential disease burden rise of >1 death per 100,000 people per year until the campaigns are implemented. For meningococcal A vaccination, short-term disruptions in 2020 are unlikely to have a significant impact due to the persistence of direct and indirect benefits from past introductory campaigns of the 1- to 29-year-old population, bolstered by inclusion of the vaccine into the routine immunisation schedule accompanied by further catch-up campaigns. Conclusions: The impact of COVID-19-related disruption to vaccination programs varies between infections and countries. Planning and implementation of campaigns should consider country and infection-specific epidemiological factors and local immunity gaps worsened by the COVID-19 pandemic when prioritising vaccines and strategies for catch-up vaccination. Funding: Bill and Melinda Gates Foundation and Gavi, the Vaccine Alliance.

Indexed as

AdolescentAdultAfricaBangladeshChildChild, PreschoolCOVID-19Disease OutbreaksHumansImmunization ProgramsInfantMeaslesMeasles VaccineMeningococcal InfectionsMeningococcal VaccinesPandemicsMeasles VaccineMeningococcal VaccinesYellow Fever VaccineCOVID-19epidemiologyglobal healthhumanmathematical modellingmeaslesmedicinemeningococcal diseasevaccinationyellow fever

Identifiers

PMID34165077
PMCPMC8263060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.